Cargando…

Cyclin E/Cdk2-dependent phosphorylation of Mcl-1 determines its stability and cellular sensitivity to BH3 mimetics

Cyclin E/Cdk2 kinase activity is frequently deregulated in human cancers, resulting in impaired apoptosis. Here, we show that cyclin E/Cdk2 phosphorylates and stabilizes the pro-survival Bcl-2 family protein Mcl-1, a key cell death resistance determinant to the small molecule Bcl-2 family inhibitors...

Descripción completa

Detalles Bibliográficos
Autores principales:	Choudhary, Gaurav S., Tat, Trinh T., Misra, Saurav, Hill, Brian T., Smith, Mitchell R., Almasan, Alexandru, Mazumder, Suparna
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2015
Materias:	Priority Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4627281/ https://www.ncbi.nlm.nih.gov/pubmed/26219338

Ejemplares similares

BH3-mimetics and BET-inhibitors elicit enhanced lethality in malignant glioma
por: Ishida, Chiaki Tsuge, et al.
Publicado: (2017)

Therapy of prostate cancer using a novel cancer terminator virus and a small molecule BH-3 mimetic
por: Sarkar, Siddik, et al.
Publicado: (2015)

Low carbohydrate diet prevents Mcl-1-mediated resistance to BH3-mimetics
por: Rubio-Patiño, Camila, et al.
Publicado: (2016)

First MCL-1-selective BH3 mimetics as potential therapeutics for targeted treatment of cancer
por: Besbes, S, et al.
Publicado: (2015)

Deubiquitinase USP13 dictates MCL1 stability and sensitivity to BH3 mimetic inhibitors
por: Zhang, Shengzhe, et al.
Publicado: (2018)

Increased MCL1 dependency leads to new applications of BH3-mimetics in drug-resistant neuroblastoma
por: Jacob, Maureen, et al.
Publicado: (2023)

Defective chromatin recruitment and retention of NHEJ core components in human tumor cells expressing a Cyclin E fragment
por: Chatterjee, Payel, et al.
Publicado: (2013)

AT101 [(-)-Gossypol] Selectively Inhibits MCL1 and Sensitizes Carcinoma to BH3 Mimetics by Inducing and Stabilizing NOXA
por: Mallick, David J., et al.
Publicado: (2020)

Side-by-side comparison of BH3-mimetics identifies MCL-1 as a key therapeutic target in AML
por: Ewald, Larissa, et al.
Publicado: (2019)

The interplay of CDK4 and CDK6 in melanoma
por: Kollmann, Karoline, et al.
Publicado: (2019)

Inhibition of MARCH5 ubiquitin ligase abrogates MCL1-dependent resistance to BH3 mimetics via NOXA
por: Subramanian, Aishwarya, et al.
Publicado: (2016)

Mitochondrial apoptosis and BH3 mimetics
por: Dai, Haiming, et al.
Publicado: (2016)

BH3 Mimetics in Hematologic Malignancies
por: Klener, Pavel, et al.
Publicado: (2021)

MCL-1 Inhibition by Selective BH3 Mimetics Disrupts Mitochondrial Dynamics Causing Loss of Viability and Functionality of Human Cardiomyocytes
por: Rasmussen, Megan L., et al.
Publicado: (2020)

BECN1 and BIM interactions with MCL-1 determine fludarabine resistance in leukemic B cells
por: Sharma, A, et al.
Publicado: (2013)

The MCL-1 BH3 Helix is an Exclusive MCL-1 inhibitor and Apoptosis Sensitizer
por: Stewart, Michelle L., et al.
Publicado: (2010)

Sorafenib Sensitizes Glioma Cells to the BH3 Mimetic ABT-737 by Targeting MCL1 in a STAT3-Dependent Manner()()
por: Kiprianova, Irina, et al.
Publicado: (2015)

Hormone-induced DNA damage response and repair mediated by cyclin D1 in breast and prostate cancer
por: Di Sante, Gabriele, et al.
Publicado: (2017)

Cyclin-dependent kinase 2 is an ideal target for ovary tumors with elevated cyclin E1 expression
por: Yang, Liu, et al.
Publicado: (2015)

On BH3 Mimetics and Ca(2+) Signaling
por: Ferdek, Pawel E., et al.
Publicado: (2017)

BET-inhibitors as sensitizers for BH3-mimetics
por: Ishida, Chiaki Tsuge, et al.
Publicado: (2017)

BH3 Mimetics for the Treatment of Prostate Cancer
por: Wolf, Philipp
Publicado: (2017)

The application of BH3 mimetics in myeloid leukemias
por: Parry, Narissa, et al.
Publicado: (2021)

Computational modeling of DLBCL predicts response to BH3-mimetics
por: Cloete, Ielyaas, et al.
Publicado: (2023)

Combined inhibition of PIM and CDK4/6 suppresses both mTOR signaling and Rb phosphorylation and potentiates PI3K inhibition in cancer cells
por: Litchfield, Lacey M., et al.
Publicado: (2020)

The deubiquitinating enzyme OTUD1 antagonizes BH3-mimetic inhibitor induced cell death through regulating the stability of the MCL1 protein
por: Wu, Lanqin, et al.
Publicado: (2019)

Regorafenib Alteration of the BCL-xL/MCL-1 Ratio Provides a Therapeutic Opportunity for BH3-Mimetics in Hepatocellular Carcinoma Models
por: Cucarull, Blanca, et al.
Publicado: (2020)

Noxa and Mcl-1 expression influence the sensitivity to BH3-mimetics that target Bcl-xL in patient-derived glioma stem cells
por: Vera, Mariana Belén, et al.
Publicado: (2022)

Preclinical efficacy of sepantronium bromide (YM155) in multiple myeloma is conferred by down regulation of Mcl-1
por: Wagner, Verena, et al.
Publicado: (2014)

BH3-mimetics: recent developments in cancer therapy
por: Townsend, Paul A., et al.
Publicado: (2021)

Sensitivity of canine hematological cancers to BH3 mimetics
por: Jegatheeson, Selvi, et al.
Publicado: (2022)

Hypericin, a potential new BH3 mimetic
por: Doroshenko, Anastasia, et al.
Publicado: (2022)

Downregulation of MCL-1 and upregulation of PUMA using mTOR inhibitors enhance antitumor efficacy of BH3 mimetics in triple-negative breast cancer
por: Li, Haolong, et al.
Publicado: (2018)

Combining BH3-mimetics to target both BCL-2 and MCL1 has potent activity in pre-clinical models of acute myeloid leukemia
por: Moujalled, Donia M., et al.
Publicado: (2018)

A direct comparison of selective BH3-mimetics reveals BCL-X(L), BCL-2 and MCL-1 as promising therapeutic targets in neuroblastoma
por: Bierbrauer, Annika, et al.
Publicado: (2020)

A same‐day assay predicts apoptotic response to combined BCL‐2 and MCL‐1 BH3‐mimetic targeting in multiple myeloma cells
por: Grundy, Martin, et al.
Publicado: (2020)

MiRNA-16-1 Suppresses Mcl-1 and Bcl-2 and Sensitizes Chronic Lymphocytic Leukemia Cells to BH3 Mimetic ABT-199
por: Ashofteh, Nooshin, et al.
Publicado: (2022)

MCL-1 and BCL-xL-dependent resistance to the BCL-2 inhibitor ABT-199 can be overcome by preventing PI3K/AKT/mTOR activation in lymphoid malignancies
por: Choudhary, G S, et al.
Publicado: (2015)

Cyclin B/CDK1 and Cyclin A/CDK2 phosphorylate DENR to promote mitotic protein translation and faithful cell division
por: Clemm von Hohenberg, Katharina, et al.
Publicado: (2022)

DNA damaging agent-induced apoptosis is regulated by MCL-1 phosphorylation and degradation mediated by the Noxa/MCL-1/CDK2 complex
por: Nakajima, Wataru, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_p263tj01r66lvu0p3i61nekadu